The cancer drug conjugate developer floated in the middle of its range, in an offering that provided exits to Takeda subsidiary Millennium Pharmaceuticals and Pfizer.

The gunfire detection technology provider floated in the middle of its range in a $30.8m IPO that gave an exit to Motorola Solutions Venture Capital.

Cancer therapy developer G1 Therapeutics has gone public in an initial public offering that gave an exit to long-time investor MedImmune Ventures.

The neurological disorder drug developer has floated in an initial public offering that gave pharmaceutical companies Sanofi and Takeda exits.

The cancer-focused antibody developer has secured $58.5m in a US flotation that involved existing investors Celgene and Eli Lilly buying more than $7m of shares.

Big data software provider Cloudera has gone public, but the gap between its market cap and the valuation at which Intel invested three years ago may be an ill omen for backers of other unicorns.

The Thomson Reuters-backed data analytics platform developer floated at the top of its range and its stock finished almost 11% up on its first day of trading.

Fintech developer Ayondo is set to list on the Singapore Exchange at a $158m valuation, giving ProSiebenSat.1 an exit.

Legend Capital has scored a significant exit as the graphite film producer, in which it held a share of almost 13%, floated in Shanghai.